| Bioactivity | Cibinetide (ARA290) is an EPO-derivative, acting as a specific agonist of erythropoietin/CD131 heteroreceptor, and used for neurological disease treatment. | ||||||
| Invitro | Cibinetide (ARA290) enhances the proliferation, migration, and resistance to H2O2-induced apoptosis of endothelial colony-forming cells (ECFCs)[1]. Cibinetide (ARA290) is an EPO-analog peptide without hematopoietic side-effects but may have neurotrophic and antidepressant effects[2]. | ||||||
| Name | Cibinetide | ||||||
| CAS | 1208243-50-8 | ||||||
| Sequence | {Glp}-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser | ||||||
| Shortening | {Glp}-EQLERALNSS | ||||||
| Formula | C51H84N16O21 | ||||||
| Molar Mass | 1257.31 | ||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||
| Storage | Sealed storage, away from moisture
*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |
Cibinetide
CAS: 1208243-50-8 F: C51H84N16O21 W: 1257.31
Cibinetide (ARA290) is an EPO-derivative, acting as a specific agonist of erythropoietin/CD131 heteroreceptor, and used
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.